TB-500 is a lab-made peptide — a short chain of amino acids — based on a natural peptide in your body called thymosin β4. Thymosin β4 is one of the tools your cells use to move around and repair damage, which is why TB-500 became popular as a "recovery" research peptide. But it comes with a catch worth understanding up front, because most websites gloss over it.
In plain terms: the parent molecule genuinely reached human trials — just not for the muscle-healing injections people actually buy.
What it is
Your cells naturally make thymosin β4, a 43-amino-acid peptide. TB-500 is a shorter synthetic piece of it — the "active region" that carries most of the biology. Think of thymosin β4 as the full tool and TB-500 as the working head of that tool. This distinction matters a lot when we get to the evidence, because the two are not interchangeable in the research.
How it's thought to work
The core trick is something called actin sequestration. Actin is the protein cells use to build their internal scaffolding — the "skeleton" they push out to crawl toward a wound. Thymosin β4 grabs loose actin building blocks and holds them in a ready-to-use pool. When a cell gets a signal to move (say, toward an injury), that pool is released and rapidly assembled into scaffolding at the cell's leading edge1.
In plain terms: it helps stockpile the raw material cells need to migrate and rebuild tissue. That's why it's studied for wound healing, and why it turns up in heart-repair research — a 2004 *Nature* study showed thymosin β4 improved cell survival and heart function after a simulated heart attack in mice1.
What the studies actually found
Here's where TB-500 is genuinely more interesting than BPC-157 — and also where the honesty matters most. Note the model *and the molecule* in each row:
| Study | Model / molecule | What happened | Year |
|---|---|---|---|
| Bock-Marquette et al.1 | Mouse heart (thymosin β4) | Better heart-cell survival and function after simulated heart attack; mapped the ILK/actin mechanism | 2004 |
| RGN-259 Phase 32 | Human eye drops (thymosin β4) | Placebo-controlled trial: 6 of 10 treated eyes fully healed a corneal defect vs 1 of 8 on placebo | 2023 |
| Scoping review4 | Review (β4 + TB-500) | Musculoskeletal evidence spans tendon, muscle and bone — but is dominated by animal and cell studies | 2026 |
Read that middle row carefully: thymosin β4 passed a real, placebo-controlled human trial — but as an eye drop for a corneal condition, not a systemic injection for tendons or muscles. That is a completely different formulation, dose, and target from the "TB-500" people inject for recovery.
The honest catch: what has — and hasn't — been tested
- Tested in humans: thymosin β4 formulations, for eye-surface conditions (Phase 2/3) and explored for cardiac repair21.
- Not tested in humans: the injectable TB-500 fragment for the muscle, tendon, and joint healing it's marketed for. Its musculoskeletal evidence is animal and cell studies only4.
So "TB-500 has human trials" is technically true and practically misleading. The molecule family reached the clinic; the specific product and use most people mean did not.
How it compares to BPC-157
TB-500 and BPC-157 are perpetually mentioned together but are structurally unrelated and work differently — BPC-157 via new blood-vessel growth, TB-500 via actin and cell migration. A practical difference is timing: TB-500's reported half-life (~2–3 days) is much longer than BPC-157's, so they appear on different research schedules (full comparison, TB-500 curve).
Regulatory status
Like BPC-157, thymosin β4 / TB-500 was placed by the FDA in "Category 2" on its 2023 bulk-substances list for compounding pharmacies — effectively "don't compound," citing safety and data gaps3. It is not an approved medicine, and US pharmacy access is restricted. This page takes no position on sourcing.
Latest research (2023–2026)
- The RGN-259 Phase 3 eye-drop trial is the strongest recent human data for the thymosin β4 molecule — a genuine placebo-controlled result, though in ophthalmology, not sports recovery2.
- A 2026 scoping review pulled together the musculoskeletal literature and confirmed the pattern: promising directions, but the tendon/muscle/bone evidence remains dominated by animal and cell studies4.
- We update this section as new trials report.
The short version
TB-500 is a fragment of a real, useful natural peptide (thymosin β4) that helps cells migrate and repair by managing actin. The parent molecule has legitimate human trial data — for eye conditions — but the injectable TB-500 used for muscle and tendon recovery has none. It's a research compound, not a medicine, and is restricted for US compounding. For the bigger picture, see what are research peptides; it's most often compared with BPC-157.